Dr. Maisel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3410 Worth St
Dallas, TX 75246Phone+1 214-370-1000Fax+1 214-370-1202
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Ohio State University HospitalResidency, Internal Medicine, 1999 - 2002
University of Pittsburgh School of MedicineClass of 1999
Certifications & Licensure
TX State Medical License 2005 - 2024
OH State Medical License 1999 - 2008- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2016 Dec 28
Publications & Presentations
PubMed
- 8 citationsPatient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.Alessandra Larocca, Xavier Leleu, Cyrille Touzeau, Joan Bladé, Agne Paner
British Journal of Haematology. 2021-10-21 - 86 citationsMelflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple MyelomaPaul G. Richardson, Albert Oriol, Alessandra Larocca, Joan Bladé, Michele Cavo
Journal of Clinical Oncology. 2021-03-01 - Simultaneous presentation of two distinct plasma cell neoplasmsDavid M. Metter, Christopher Maisel, John R. Krause
Proceedings. 2018-10-19
Abstracts/Posters
- The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Basel...Christopher Maisel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 S...Christopher Maisel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Data from Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual MeetingSeptember 11th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
